10/07/2024 - 15:02

Radiopharm unveils landmark human lung cancer trial

10/07/2024 - 15:02


Save articles for future reference.

Radiopharm Theranostics has kicked off the first phase of clinical trials testing its “RAD 204” treatment aimed at beating the most common type of lung cancer – non-small cell lung cancer (NSCLC) – after dosing its first patient in New South Wales. The first in-human trial at the Wollongong Hospital has been designed to assess the safety and tolerability of the company’s innovative radiopharmaceutical therapy.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options